dotinurad: Clinical Trials

6 trials of dotinurad, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 1 recruiting. 6 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 26Completed 5, Recruiting 1
Phase 11Completed 1

Follow dotinurad: new trials by email Literature Review of dotinurad trials Research Report on dotinurad

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants
Dotinurad, Placebo - Gout
Phase 2RecruitingCrystalys Therapeutics902026-05-082026-09-28
Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia
dotinurad, dotinurad + allopurinol, allopurinol - Gout, Hyperuricemia
Phase 1 / Phase 2CompletedUrica Therapeutics Inc.202023-10-042026-06-10
Study of FYU-981 in Hyperuricemia (Effect on Two Hyperuricemic Types)
FYU-981, Topiroxostat - Hyperuricemia
Phase 2CompletedFuji Yakuhin Co., Ltd.242016-07-012018-08-21
Clinical Pharmacology of FYU-981 (Effect on QT/QTc Interval)
FYU-981, Placebo, Moxifloxacin - Healthy
Phase 2CompletedFuji Yakuhin Co., Ltd.482015-08-012017-09-08
Study of FYU-981 in Hyperuricemia With or Without Gout
FYU-981, Placebo - Hyperuricemia
Phase 2CompletedFuji Yakuhin Co., Ltd.2002015-05-012017-02-14
Study of FYU-981 in Hyperuricemia With or Without Gout
FYU-981 High dose, (Oral daily dosing for 8 weeks), FYU-981 Middle dose, (Oral daily dosing for 8 weeks), FYU-981 Low dose, (Oral daily dosing for 8 weeks) - Hyperuricemia
Phase 2CompletedFuji Yakuhin Co., Ltd.802014-01-012015-01-26

Conditions studied

Hyperuricemia (4)  ·  Gout (2)

Sponsors

Fuji Yakuhin Co., Ltd. (4)  ·  Crystalys Therapeutics (1)  ·  Urica Therapeutics Inc. (1)

Countries

Japan (4)  ·  United States (2)

Results publications

PMID 31734820, PMID 31754882, PMID 31792640